Preclinical Cancer Models for Immunotherapy DevelopmentAvailable Methods:
Our team of scientists has extensive experience in various cancer models and immuno-oncology studies. We specialize in murine solid tumors for both subcutaneous and orthotopic models, with an emphasis on disease progression, biomarkers and immunophenotyping.
Some examples of our syngeneic cancer models include:
- 4T1 Metastatic Breast Cancer
- Renca kidney cancer is a syngeneic model of metastatic renal cell carcinoma (RCC)
- Lewis lung cancer (LLC) is a syngeneic model of lung carcinoma
We are able to put any cancer model in place and investigate all immunological and related biomarkers in addition to all cancer-related parameters. Studies to identify the impacts of co-morbidities such as obesity or compounding factors such as the microbiome can be customized.
Specialty cancer research areas include:
- Longitudinal tumor monitoring
- Longitudinal blood phenotyping (immune cell distribution, biomarkers, etc.)
- End time-point primary tumor evaluation and metastatic tissue evaluation (for some models)
- Tumor tissue-specific cellular analysis using intravascular staining (cells: epithelial, endothelial, immune etc.)
- Cancer biomarker analysis in tumor tissues
- Biomarker development and analysis (blood, tumor tissue, spleen, lymph node etc.)
- Histological grading and evaluation of tumor specific tissue (H&E, IHC, etc.)
- Disease super-imposition
Highlight: The Renca Renal Cancer Model
A metastatic model to study novel immunotherapeutic approaches.
Novel immunotherapeutic approaches have shown efficacy in human renal cell carcinoma (RCC), demonstrating an exciting area of therapeutic potential for this cancer. Renca kidney cancer is a syngeneic, mouse model of metastatic renal cell carcinoma (RCC) in BALB/c mice. Renca cells can be injected subcutaneously or orthotopically. In the orthotopic model, cells are introduced directly into the kidney, wherein they form tumors that metastasize to secondary organs such as the lungs.